MARKET

FDMT

FDMT

4D Molecular Therapeutics Inc.
NASDAQ
8.99
+0.60
+7.15%
After Hours: 8.82 -0.17 -1.89% 19:38 02/06 EST
OPEN
8.50
PREV CLOSE
8.39
HIGH
9.00
LOW
8.42
VOLUME
778.80K
TURNOVER
--
52 WEEK HIGH
12.34
52 WEEK LOW
2.235
MARKET CAP
458.56M
P/E (TTM)
-2.4012
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FDMT last week (0126-0130)?
Weekly Report · 6d ago
Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)
Benzinga · 01/28 14:01
4D Molecular Therapeutics Price Target Announced at $33.00/Share by Barclays
Dow Jones · 01/28 13:47
4D Molecular Therapeutics Initiated at Overweight by Barclays
Dow Jones · 01/28 13:47
4D Molecular assumed with an Overweight at Barclays
TipRanks · 01/27 21:27
Bank of America Securities Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)
TipRanks · 01/27 13:26
4D Molecular Therapeutics Restructures Equity via Warrant Exchange
TipRanks · 01/26 21:36
4D Molecular Therapeutics Issues Pre-Funded Warrants in Exchange for Common Stock
Reuters · 01/26 21:06
More
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.